Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 3/2019

01-09-2019 | Obesity | Obesity Treatment (CM Apovian, Section Editor)

FSP27 and Links to Obesity and Diabetes Mellitus

Author: Shakun Karki

Published in: Current Obesity Reports | Issue 3/2019

Login to get access

Abstract

Purpose of Review

Obesity is a pandemic, yet preventable healthcare problem. Insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular complications are core manifestation of obesity. While adipose tissue is a primary site of energy storage, it is also an endocrine organ, secreting a large number of adipokines and cytokines. Nonetheless in obesity, the secretion of cytokines and free fatty acids increases significantly and is associated with the degree of adiposity and insulin resistance. Fat-specific protein 27 (FSP27) has emerged as one of the major proteins that promote physiological storage of fat in adipose tissue.

Recent Findings

Review of number of recent findings suggests that FSP27 plays a crucial role in physiological storage of fat within the adipose tissue especially in humans. However, in disease conditions such as obesity, FSP27 may contribute to ectopic fat accumulation in non-adipose tissue.

Summary

More studies are required to highlight the tissue-specific role of FSP27, especially in humans.
Literature
1.
Ogden CL, Carroll MD, Fryar CD, Flegal KM: Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief 2015(219):1–8.
2.
Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. Jama. 2012;307(5):491–7.CrossRefPubMed
3.
Marie Ng TF, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:11.CrossRef
4.
Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity. 2008;16(10):2323–30.CrossRefPubMed
5.
Britton KA, Fox CS. Ectopic fat depots and cardiovascular disease. Circulation. 2011;124(24):e837–41.CrossRefPubMed
6.
Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB, et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA study. J Am Coll Cardiol Img. 2014;7:1221–35.CrossRef
7.
Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391–406.CrossRefPubMedPubMedCentral
8.
Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131–41.CrossRefPubMed
9.
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–80.CrossRefPubMed
10.
Karki S, Ngo DT, Bigornia SJ, Farb MG, Gokce N. Insulin resistance: a key hterapeutic target for cardiovascular risk reduction in obese patients? Expert Rev Endocrinol Metab. 2014;9(2):3.CrossRef
11.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.CrossRefPubMed
12.
13.
Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2012;32(9):2052–9.CrossRefPubMedPubMedCentral
14.
Karki S, Farb MG, Ngo DT, Myers S, Puri V, Hamburg NM, et al. Forkhead box o-1 modulation improves endothelial insulin resistance in human obesity. Arterioscler Thromb Vasc Biol. 2015;35(6):1498–506.CrossRefPubMedPubMedCentral
15.
Zhang HH, Huang J, Duvel K, Boback B, Wu S, Squillace RM, et al. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One. 2009;4(7):e6189.CrossRefPubMedPubMedCentral
16.
Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrology, Dialysis and Transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. 2011;26(1):28–35.CrossRef
17.
Fonseca V, John-Kalarickal J: Type 2 diabetes mellitus: epidemiology, genetics, pathogenesis, and clinical manifestations. In: Poretsky L, (ed). Principles of diabetes mellitus. Boston: Springer; 2010:203–220.
18.
Koutsari C, Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res. 2006;47(8):1643–50.CrossRefPubMed
19.
Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 2009;42(13–14):1331–46.CrossRefPubMed
20.
21.
22.
Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97(12):2859–65.CrossRefPubMedPubMedCentral
23.
Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145(5):2273–82.CrossRefPubMed
24.
Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest. 2011;121(6):2102–10.CrossRefPubMedPubMedCentral
25.
Xu S, Zhang X, Liu P. Lipid droplet proteins and metabolic diseases. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5 Pt B):1968–83.CrossRefPubMed
26.
Puri V, Konda S, Ranjit S, Aouadi M, Chawla A, Chouinard M, et al. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. J Biol Chem. 2007;282(47):34213–8.CrossRefPubMed
27.
28.
Keller P, Petrie JT, De Rose P, Gerin I, Wright WS, Chiang SH, et al. Fat-specific protein 27 regulates storage of triacylglycerol. J Biol Chem. 2008;283(21):14355–65.CrossRefPubMedPubMedCentral
29.
Gong J, Sun Z, Wu L, Xu W, Schieber N, Xu D, et al. Fsp27 promotes lipid droplet growth by lipid exchange and transfer at lipid droplet contact sites. J Cell Biol. 2011;195(6):953–63.CrossRefPubMedPubMedCentral
30.
Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.CrossRefPubMedPubMedCentral
31.
Puri V, Ranjit S, Konda S, Nicoloro SM, Straubhaar J, Chawla A, et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A. 2008;105(22):7833–8.CrossRefPubMedPubMedCentral
32.
Danesch U, Hoeck W, Ringold GM. Cloning and transcriptional regulation of a novel adipocyte-specific gene, FSP27. CAAT-enhancer-binding protein (C/EBP) and C/EBP-like proteins interact with sequences required for differentiation-dependent expression. J Biol Chem. 1992;267(10):7185–93.PubMed
33.
Nishino N, Tamori Y, Tateya S, Kawaguchi T, Shibakusa T, Mizunoya W, et al. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J Clin Invest. 2008;118(8):2808–21.PubMedPubMedCentral
34.
Toh SY, Gong J, Du G, Li JZ, Yang S, Ye J, et al. Up-regulation of mitochondrial activity and acquirement of brown adipose tissue-like property in the white adipose tissue of fsp27 deficient mice. PLoS One. 2008;3(8):e2890.CrossRefPubMedPubMedCentral
35.
Zhiqi Sun JG, Wu H, Xu W, Wu L, Xu D, Gao J, et al. Perilipin1 promotes unilocular lipid droplet formation through the activation of Fsp27 in adipocytes. Nat Commun. 2013;4:13.
36.
• Langhi C, Arias N, Rajamoorthi A, Basta J, Lee RG, Baldan A. Therapeutic silencing of fat-specific protein 27 improves glycemic control in mouse models of obesity and insulin resistance. J Lipid Res. 2017;58(1):81–91 Recent study indicated that silencing of FSP27, presumeably throughout the body, in mouse model of obesity and insulin resistance was beneficial. CrossRefPubMed
37.
• Rajamoorthi A, Lee RG, Baldan A. Therapeutic silencing of FSP27 reduces the progression of atherosclerosis in Ldlr(−/−) mice. Atherosclerosis. 2018;275:43–9 Recent study indicating that silencing of FSP27 in LDLR−/− mice slowdown the progression of atherosclerosis. CrossRefPubMedPubMedCentral
38.
• Grahn TH, Kaur R, Yin J, Schweiger M, Sharma VM, Lee MJ, et al. Fat-specific protein 27 (FSP27) interacts with adipose triglyceride lipase (ATGL) to regulate lipolysis and insulin sensitivity in human adipocytes. J Biol Chem. 2014;289(17):12029–39 Using human adipocytes, these researches demonstrated that silencing of FSP27 increased lipolysis and impaired insulin signlaing and overexpression of FSP27 protected human adipocytes from FFA induced insulin resistance, which is opposite of what reference 36–37 demonstrated.CrossRefPubMedPubMedCentral
39.
• Tanaka N, Takahashi S, Matsubara T, Jiang C, Sakamoto W, Chanturiya T, et al. Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J Biol Chem. 2015;290(5):3092–105 This murine model of adipose specific deletion of FSP27 suggest that disruption of FSP27 in adipose tissue, thus losing the ability to store TG in adipose tissue, creates an unfavorable secondary effect such as hepatosteatosis and insulin resistance, especially when animals were fed high fat. CrossRefPubMed
40.
• Zhou L, Park SY, Xu L, Xia X, Ye J, Su L, et al. Insulin resistance and white adipose tissue inflammation are uncoupled in energetically challenged Fsp27-deficient mice. Nat Commun. 2015;6:5949 Zhou and colleagues also demonstrated that disruption of FSP27 in mice, generated systemic insulin resistance and adipose tissue inflammation, again in energetically challenged condition. CrossRefPubMed
41.
Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280–7.CrossRefPubMedPubMedCentral
42.
•• Moreno-Navarrete JM, Ortega F, Serrano M, Rodriguez-Hermosa JI, Ricart W, Mingrone G, et al. CIDEC/FSP27 and PLIN1 gene expression run in parallel to mitochondrial genes in human adipose tissue, both increasing after weight loss. Int J Obes. 2014;38(6):865–72 This study compiles results from 80 individuals, and highlights changes in expression of FSP27 in human obesity and insulin resistance. Levels of FSP27, especially in visceral obesity were significantly lower than that of subcutaneous fat in obeisty, and were negatively associated to HOMA IR and BMI. Levels of FSP27 goes up after significant weight-loss. CrossRef
43.
Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, et al. Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-a, in human obesity. Circulation. 2014;130(13):1072–80.CrossRefPubMedPubMedCentral
44.
Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue FTO gene expression and adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes mellitus and in health. Obes Surg. 2010;20(1):108–13.CrossRefPubMed
45.
Boden G. Obesity and free fatty acids. Endocrinol Metab Clin N Am. 2008;37(3):635–46 viii-ix.CrossRef
46.
Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010–3.CrossRefPubMed
47.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity Rev. 2010;11(1):11–8.CrossRef
48.
Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, et al. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002;87(8):3902–10.CrossRefPubMed
49.
Glick SM, Roth J, Yalow RS, Berson SA. Immunoassay of human growth hormone in plasma. Nature. 1963;199:784–7.CrossRefPubMed
50.
Roth J, Glick SM, Yalow RS. Bersonsa: hypoglycemia: a potent stimulus to secretion of growth hormone. Science. 1963;140(3570):987–8.CrossRefPubMed
51.
Sharma VM, Vestergaard ET, Jessen N, Kolind-Thomsen P, Nellemann B, Nielsen TS, et al. Growth hormone acts along the PPARgamma-FSP27 axis to stimulate lipolysis in human adipocytes. Am J Phys Endocrinol Metab. 2019;316(1):E34–42.CrossRef
52.
• Sharma R, Luong Q, Sharma VM, Harberson M, Harper B, Colborn A, et al. Growth hormone controls lipolysis by regulation of FSP27 expression. J Endocrinol. 2018;239(3):289–301 Recent study by Sharma and collegues demonstrates that levels of FSP27 in adispoe tissue goes down with growth hormone infusion in healthy volunteers compared to Salin infusion. Excess growth hormone has been linked with adverse health outcomes. CrossRefPubMedPubMedCentral
53.
Hall AM, Brunt EM, Klein S, Finck BN. Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss. Obesity. 2010;18(2):417–9.CrossRefPubMed
54.
• Xu MJ, Cai Y, Wang H, Altamirano J, Chang B, Bertola A, et al. Fat-specific protein 27/CIDEC promotes development of alcoholic steatohepatitis in mice and humans. Gastroenterology. 2015;149(4):1030–41 e1036. Study by Xu and collegues indicates that disruption of FSP27 in adipose tissue promote development of heapatic steaohepatitis in both mice and humans, highlighting the importance of FSP27 in proper storage of fat. CrossRefPubMed
55.
Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem. 2003;278(1):498–505.CrossRefPubMed
56.
Matsusue K, Kusakabe T, Noguchi T, Takiguchi S, Suzuki T, Yamano S, et al. Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab. 2008;7(4):302–11.CrossRefPubMedPubMedCentral
57.
• Rajamoorthi A, Arias N, Basta J, Lee RG, Baldan A. Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate. J Lipid Res. 2017;58(11):2127–38 Recent study indicating that silencing FSP27 and in combination with PPARα inhibitor protects mice from diet-induced hepatic steatohepatitis. CrossRefPubMedPubMedCentral
58.
Vila-Brau A, De Sousa-Coelho AL, Goncalves JF, Haro D, Marrero PF. Fsp27/CIDEC is a CREB target gene induced during early fasting in liver and regulated by FA oxidation rate. J Lipid Res. 2013;54(3):592–601.CrossRefPubMedPubMedCentral
59.
Tamori Y. FSP27 is a potent player regulating lipid storage in liver as well as adipose tissue. Diabetol Internat. 2013;4:3.CrossRef
60.
Xu X, Park JG, So JS, Lee AH. Transcriptional activation of Fsp27 by the liver-enriched transcription factor CREBH promotes lipid droplet growth and hepatic steatosis. Hepatology. 2015;61(3):857–69.CrossRefPubMed
61.
• Puri V. FSP27β, a novel fat-specific protein 27 isoform promoting hepatic steatosis. Hepatology. 2014;61(3):3 This review summarizes presence of different isoforms of FSP27, specific to adipose tissue and the liver.
Metadata
Title
FSP27 and Links to Obesity and Diabetes Mellitus
Author
Shakun Karki
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Obesity Reports / Issue 3/2019
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-019-00343-3

Other articles of this Issue 3/2019

Current Obesity Reports 3/2019 Go to the issue

Obesity Treatment (CM Apovian, Section Editor)

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Food Preferences and Potential Mechanisms Involved

Obesity Treatment (CM Apovian, Section Editor)

Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity

Obesity Treatment (CM Apovian, Section Editor)

Lessons Learned from the POUNDS Lost Study: Genetic, Metabolic, and Behavioral Factors Affecting Changes in Body Weight, Body Composition, and Cardiometabolic Risk

Obesity Treatment (CM Apovian, Section Editor)

Nonalcoholic Fatty Liver Disease and Obesity Treatment

Obesity Treatment (CM Apovian, Section Editor)

Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity

Obesity Treatment (CM Apovian, Section Editor)

Extrinsic and Intrinsic Immunometabolism Converge: Perspectives on Future Research and Therapeutic Development for Obesity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits